XML 84 R67.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Financial Instruments - Other Noncurrent Liabilities (Detail) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | ---
Apr. 30, 2018 | Dec. 31, 2017 | Aug. 31, 2017 | Jun. 30, 2017 | Sep. 30, 2018 | Jul. 01, 2018 | Sep. 30, 2018 | Aug. 31, 2018 | Jun. 30, 2018
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  | $ 36,562 |  |  | $ 36,012 |  | $ 36,012 |  |
Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net | [1] |  | $ 34,765 |  |  | 34,337 |  | 34,337 |  |
EU [Member] | Mylotarg [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Term over which fixed annual payments are to be made |  | 10 years |  |  |  |  |  |  |  |
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement |  | $ 301 |  |  |  |  |  |  |  |
EU [Member] | Mylotarg [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  | $ 240 |  |  |  |  |  |  |  |
Lump sum payment for liability buyout |  |  |  |  |  |  |  |  |  | $ 224
Non-cash gain from buyout transaction |  |  |  |  |  |  | $ 17 | 17 |  |
EU [Member] | Besponsa [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Term over which fixed annual payments are to be made |  |  |  |  | 9 years |  |  |  |  |
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement |  |  |  |  | $ 148 |  |  |  |  |
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  | $ 123 | 121 |  | 121 |  |
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | 3 |  | 3 |  |
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | 118 |  | 118 |  |
U.S. [Member] | Bosulif [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Term over which fixed annual payments are to be made |  |  | 10 years |  |  |  |  |  |  |
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement |  |  | $ 416 |  |  |  |  |  |  |
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  | $ 364 |  |  | 208 |  | 208 |  |
Lump sum payment for liability buyout |  |  |  |  |  |  |  |  | $ 71 |
Non-cash gain from buyout transaction |  |  |  |  |  | 9 |  |  |  |
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | 23 |  | 23 |  |
U.S. [Member] | Bosulif [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | 185 |  | 185 |  |
U.S. [Member] | Besponsa [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Term over which fixed annual payments are to be made |  |  |  | 9 years |  |  |  |  |  |
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement |  |  |  | $ 296 |  |  |  |  |  |
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  | $ 248 |  | 240 |  | 240 |  |
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | 7 |  | 7 |  |
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member] |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |
Finite-lived intangible assets, net |  |  |  |  |  | $ 233 |  | $ 233 |  |
[1] | The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas, and (ii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).

X
- Definition Research and Development Arrangement, Aggregate Payment Obligation + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research and Development Arrangement, Aggregate Payment Obligation, Term + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
Namespace Prefix: | pfe_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement, Gain From Liability Extinguishment + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Liability Buyout, Amount + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MylotargMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BesponsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |